Clinical Trial of Comparative Study of GB221 Pharmacokinetics
The primary objective is to assess the safety of a single dose of GB221 compared to Herceptin® when administered as a single IV injection at a dose of 8 mg/kg. The secondary objective of the study is to assess the pharmacokinetics of GB221 compared to Herceptin®.
Metastatic Breast Cancer
DRUG: Coprelotamab Injection|DRUG: Trastuzumab Injection
physical examination, physical examination, Up to 84 days|adverse event, adverse event, Up to 84 days|blood pressure, blood pressure, Up to 84 days|heart rate, heart rate, Up to 84 days|respiration rate, respiration rate, Up to 84 days|oxygen saturation, oxygen saturation, Up to 84 days|temperature, temperature, Up to 84 days
C max, C max, Up to 84 days|t max, t max, Up to 84 days|AUC, AUC, Up to 84 days|CL, CL, Up to 84 days|t ½, t ½, Up to 84 days|V, V, Up to 84 days
The primary objective is to assess the safety of a single dose of GB221 compared to Herceptin® when administered as a single IV injection at a dose of 8 mg/kg. The secondary objective of the study is to assess the pharmacokinetics of GB221 compared to Herceptin®.